Novartis Canakinumab approved for use in axial spondyloarthritis with radiographic evidence of ankylosing spondylitis in China.

On February 3rd, Novartis announced that its innovative biologic drug Cosentyx has been approved by the National Medical Products Administration for a new indication, for the treatment of active axial spondyloarthritis in adults who have had an inadequate response to non-steroidal anti-inflammatory drugs (with elevated markers of inflammation and/or magnetic resonance imaging evidence, but no radiographic evidence of sacroiliitis).